SMKG yields 40816.33% · ABBV yields 3.06%● Live data
📍 SMKG pulled ahead of the other in Year 1
Combined, SMKG + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SMKG + ABBV for your $10,000?
Smart Card Marketing Systems Inc., doing business as PaymentActiveNetwork, operates as a fintech solutions provider that delivers a cloud-based EMV MPOS, and EPOS Host platform to issuing and acquiring banks, telecoms, and global enterprises. The company offers EmphasisPay that delivers advisory and technology solutions for payment acquirers and issuers; Mtickets.events that allows users to create an event or events and issue mobile tickets; Genorocity.com, a web publication portal and mobile platform that enables retailers, property managers, and event promoters; and Check21SAAS.com, a remote check deposit solution. It also provides VelocityMPOS, a customizable EMV MPOS solution for Retail or 'On the Go business'; and Articul8te.com for individuals and businesses to create and publish articles. In addition, the company offers advisory and product development services. Smart Card Marketing Systems Inc. has strategic partnership with Quotientica Pvt Ltd. to deliver an AI driven fraud detection system to banks and financial institutions. The company was founded in 2006 and is based in Wilmington, Delaware. Smart Card Marketing Systems Inc. is a former subsidiary of Performance Optician Software Corporation.
Full SMKG Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.